1 / 43

Acyl carnitine analysis: Pitfalls & Problems

Acyl carnitine analysis: Pitfalls & Problems. Rachel Webster Birmingham Children’s Hospital. Carnitine. Quaternary ammonium compound Biosynthesised from lysine and methionine Liver and kidney Transports fatty acids from cytosol into mitochondria

taylor
Download Presentation

Acyl carnitine analysis: Pitfalls & Problems

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acyl carnitine analysis:Pitfalls & Problems Rachel Webster Birmingham Children’s Hospital

  2. Carnitine Quaternary ammonium compound Biosynthesised from lysine and methionine Liver and kidney Transports fatty acids from cytosol into mitochondria Facilitates the production of energy from fat

  3. Dietary fat Major component of dietary fat is triglycerides 1 glycerol 3 fatty acids

  4. Energy production Preferentially use carbohydrates Glucose Glycogen Hypoglycaemia (fasting, illness, infection) Fat metabolism Mitochondrial oxidation of fatty acids provides upto 80% of total requirement Protein metabolism Last resort Periods of excessive starvation

  5. Triglyceride breakdown

  6. Transport into mitochondria Acyl-CoA Carnitine Transporter

  7. Acyl co-A dehydrogenase species SCAD C4-C6 MCAD C4-C12 LCAD C8-C20 VLCAD C12-C24

  8. Energy yield Fat 106 ATP 1 molecule of C16 palmitate Carbohydrate 36 ATP 1 molecule of glucose  Why we only need a small amount of fat in our diets

  9. Defects Carnitine deficiency CPT-1 deficiency CPT-2 deficiency CACT (carnitine transporter defect) VLCADD LCADD MCADD SCADD Plus many more!!!  all differing acyl carnitine profiles

  10. Free and acyl carnitine analysis Native (underivatised) acyl carnitines Butylated derivatives Carboxylic acid group is esterified Both fragment to yield a common m/z 85 daughter ion

  11. BCH Practice Paired DBS and plasma CIL NSK-B IS kit Derivatise Report Quantitative free carnitine (plasma) Qualitative acyl carnitine interpretation (plasma & DBS) Quantitate any relevant species Underivatised Urgent samples Unusual peaks

  12. BCH Practice DBS and Plasma Plasma Acute scenario DBS Better overview of long-term status Some disorders are better represented in different sample types GA-1 HMG CoA Lyase deficiency

  13. Sample preparation Derivatised Underivatised 3mm DBS 10ul plasma 200ul IS c stable isotopes 30min elution Dry Protein crash Butanol HCL Dry Direct flow injection +ve ESI MSMS

  14. LC-MSMS

  15. Acyl carnitine fragmentation

  16. Precursor ion scan

  17. BCH Practice • Acyl carnitines • Parents m/z 85 scan • Currently generating age-related reference ranges • Free carnitine quantitation • MRM 218 > 85 • Ref range 13-53 umol/L • Linearity 300 umol/L • Chromsystems Neonatal Screening IQC • CDC EQA DBS Scheme • ERNDIM Free carnitine Scheme

  18. Internal Standard - Deriv C0d9 C2d3 C16d3 C5d9 C14d9 C4d3 C3d3 C8d3

  19. Advantages of derivatisation Increased mass compared to underivitised avoids low mass contaminants solvent adducts Less affected by ‘isobaric conflicts’ dicarboxylic acylcarnitines C3DC hydroxycarboxylic acylcarnitines [OH]C4 Better ionisation of dicarboxylics 2 COOH gps Double derivitisation Increased positivity  excellent for +ve ESI Culture established worldwide published data better understanding of analysis

  20. Underiv - ?Malonyl/OHBut Patient 1 m/z 248 Patient 2

  21. Deriv - ? Malonyl/OHBut m/z 360 ie malonyl carnitine C3DC Patient 1 m/z 304 ie hydroxy butyryl carnitine Patient 2

  22. Disadvantages to derivatisation For big batches (screening)…time, effort, cost and acid corrosion……!!! More steps to method - potential for more errors Hydrolysis during derivatisation loss of acylcarnitines increase in free carnitine Isobaric conflict Acetylcarnitine and glutamate m/z 260…esp DBS dicarboxylic acylcarnitines and hydroxyacylcarnitines [OH]C8 [OH]C10  ‘pseudo-glutaryl carnitinaemia’ in MCADD

  23. SCADD Diagnostic peak m/z 288

  24. MCADD - crisis Diagnostic peak m/z 344

  25. VLCADD Diagnostic peak m/z 426

  26. Ketotic Peaks m/z 260, 304 & 426

  27. GA1 DBS vs Plasma - Deriv Diagnostic peak m/z 388

  28. GA1 Plasma Deriv vs Underiv Diagnostic peak m/z 388 Diagnostic peak m/z 275

  29. GA2 Diagnostic C4 – C18

  30. b ketothiolase deficiency Diagnostic peaks m/z 300 & 318

  31. MMA Diagnostic peaks m/z 274 & 374

  32. PA Diagnostic peak m/z 274

  33. IVA Diagnostic peak m/z 302

  34. Malonic aciduria Diagnostic peak m/z 360

  35. PMB Increased free and short chains

  36.  Acylcarnitine MRM (butyl) MRM (underiv.] Disorder C0 218 > 85 162 > 85 PCD C2260 > 85 204 > 85 (Glutamate) C3 274 > 85 218 > 85 MMA; PA C4 288 > 85 232 > 85 EMA;SCAD; GA2 C5:1 300 > 85 244 > 85 PA; BkT C5 302 > 85 246 > 85 IVA; GA2 C4-OH304 > 85248 > 85 (Ketosis) C6 316 > 85 260 > 85 GA2 (MCAD) C5-OH318 > 85262 > 85 Biot;IVA;BkT;3HMG C8344 > 85288 > 85MCAD / [?] C3-DC360 > 85248 > 85 Malonic Aciduria C8-OH360 > 85304 > 85 (Metab Crisis) C10:1 370 > 85 314 > 85 MCAD C10 372 > 85 316 > 85 GA2 C4-DC374 > 85262 > 85 [MMA] C5-DC388 > 85276 > 85 GA1 ; (GA2) C10-OH388 > 85332 > 85 (Metab crisis) C12:1 398 > 85 342 > 85 [B-oxidn] C12 400 > 85 344 > 85 (B-oxidn]

  37. Plasticisers Diagnostic peak m/z 288

  38. Additional peaks Benzoate m/z 332 Phenylbutyrate m/z 336 Cefotaxime m/z 470 & 426

  39. Cefotaxime Two peaks m/z 426 & 470

  40. Conclusions Isobaric compounds Deriv vs underiv Which ever method run routinely must be ready to run other way for confirmation Plasma vs DBS Plasticisers

More Related